This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sector Watch: Big Pharma Misses Out on the Rally

Not every sector is feeling the benefits of the Fed rate cut.

Pharmaceutical companies, often a safe haven in a troubled market, are moving to the downside during today's massive market rally. While the Dow Jones Industrial Average is soaring more than 400 points and the Nasdaq is gaining more than 200 points, indexes such as the American Stock Exchange Pharmaceutical Index, which is down 2.6% today, show drug companies slipping into negative territory. The Dow Jones U.S. Pharmaceutical Index is down 2.8% so far today. Meanwhile, the Dow Jones U.S. Pharmaceutical & Biotech Index, a combo platter of both drug companies and medical-based tech stocks, is feeling the strong downside pull of the pharmaceuticals, as it has lost 1.4%.

Biotechnology companies, on the other hand, are enjoying a nice run, with the Nasdaq Biotech Index up a solid 6.7% today.

"It's an interest rate thing," says Emily Hall, an analyst at Morningstar. "Pharmaceuticals are often a place where people hide when the markets are nasty."

But when the tables turn and the markets head uphill, funds flow out of the drug manufacturers and into the more Fed-positive sectors, such as financials, tech and cyclicals. Bristol-Myers Squibb (BMY), a big cap pharmaceutical producer, is down $3.21, or 5.4%, to $56.64.

Pfizer (PFE), another big name drug company, reported strong first-quarter earnings this morning, but the shares dropped $1.33, or 3.1%, to $41.10. Merck (MRK) is down $2.62, or 3.2%, to $78.23.

Sector stalwarts Johnson & Johnson (JNJ) and American Home Products (AHP) are both feeling the sector ills today. J&J is down 2.4%, and American Home is losing 2.1%.

Hall sees the move as a "sector rotation out of pharmaceuticals. You don't need them as as much of a safe have as before."

The pharmaceutical sector has been on a pretty steady rise since the end of March, as have other sectors, such as the financials. But should the market continue on an upswing, traders think that the drugs sector will continue to fall.

"For a while they did better than other sectors," says Ned Collins, executive vice president of U.S. stocks at Daiwa Securities America. "People felt like there was a possibility of weakness in the dollar and other problems that they could face in their sales overseas, so this was a good opportunity to get into other areas."

Collins cites the strong liquidity of today's market as incentive for investors to sell their drug stocks and get into areas that may be more profitable in the near term. "With the liquidity in the market today, investors are taking the opportunity to make big plays on big swings," says Collins.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs